NOTIFICATION OF TRADE AMONG PRIMARY INSIDERS

On October 13 2008 mandatory notifications of trade among primary insiders of DiaGenic ASA took place. The transactions made no changes in the net exposure among the insiders. The transactions are described in more detail below.

Director and board member Praveen Sharma has redeemed the forward contract for 300,000 shares entered into on September 23 2008 at a forward price of NOK 3.135 per share, through the purchase of 300,000 shares at NOK 3.00 per share. Subsequently Sharma has sold 400,000 shares at NOK 3.00 per share, and entered into a 6 month forward contract for the purchase of 400,000 shares at NOK 3,14 per share. After the transaction Sharma controls a total of 3,170,000 shares in DiaGenic, unchanged by the transaction.

Håkon Sæterøy, Chairman of the Board of DiaGenic ASA, has through his wholly-owned company INVESTOR Corporate AS redeemed the forward contract for 100,000 shares entered into on September 23 2008 at a forward price of NOK 3.135 per share, through the purchase of 100,000 shares at NOK 3.00 per share. Subsequently INVESTOR Corporate AS has sold 135,000 shares at NOK 3.00 per share, and Håkon Sæterøy has entered into a 6 month forward contract for the purchase of 135,000 shares at NOK 3.14 per share. Sæterøy`s overall exposure in the Company is unchanged at a total of 1,303,478 shares.

Contact:
MD PhD Erik Christensen, Managing Director
Telephone: +47 95939918
e-mail: erik.christensen@diagenic.com

About Us

NEL ASA is a leading global supplier of hydrogen technology for industrial / energy purposes, and has made over 500 deliveries in more than 50 countries. The company's main products are hydrogen production plants based on water electrolysis, complete hydrogen stations for transport and renewable energy storage solutions. The company has its roots from the hydrogen activities of Norsk Hydro, which dates back to 1927. The company also has a number of patents related to tests for early detection and diagnosis of diseases.

Subscribe